摘要
目的探讨和研究利伐沙班对于脊髓损伤术后静脉血栓栓塞性疾病的影响和安全性。方法前瞻性分析和比较2010—2013年于该院明确诊断为颈或胸脊髓损伤并行手术治疗的患者83例,其中40例于术后给予口服利伐沙班(观察组),43例未给予抗血栓药物(对照组)。结合随访资料,评价并比较二组患者在术后关于静脉血栓栓塞性疾病的各临床指标以及利伐沙班的安全性指标。结果利伐沙班组与对照组相比并未显著增加术后引流量、出血风险和不良风险(P>0.05),但利伐沙班组的深静脉血栓发病率和肺栓塞的发病率均显著低于对照组(P<0.05)。结论利伐沙班可以有效降低脊髓损伤术后患者静脉血栓栓塞性疾病的发病率,并不增加术后出血等不良风险,在临床工作中可以进一步使用。
Objective To analyze and investigate the effieacy and safety on venous thromboembolism after spinal cord injury surgery. Methods A prospective clinical trial was carried out in 83 consecutive patients with spinal cord injury treated by surgery from 2010 to 2013. Patients were randomly divided into two groups according to the date of admission. A group of patients （40 cases） were taken Rivaroxaban, another group of patients （43 cases） was the control group. Clinical outcomes were evaluated to compare the efficacy and safety between the two groups. Results Rivaroxaban didn＇t increase the volume of drainage, the risk of postoperative bleeding and function impairment compared with control group（P〈0.05）, but Rivaroxaban could significantly reduce the incidence of venous thromboembolisrn after spinal cord injury surgery （P〈0.05）. Conclusions Rivaroxaban can significantly reduce the incidence of postoperative deep vein thrombosis and pulmonary embolism of spinal cord injury which does not increase the risk of postoperative bleeding, wound infection and liver function impairment. It can be further carried out in clinic.
出处
《中国煤炭工业医学杂志》
2015年第5期692-695,共4页
Chinese Journal of Coal Industry Medicine
基金
国家自然科学基金项目(81201633)
